These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36304224)

  • 1. Bullous Pemphigoid Associated with Dipeptidyl Peptidase 4 Inhibitors for the Treatment of Type 2 Diabetes: A Multicenter Study in Istanbul.
    Ugurer E; Ozkur E; Altunay IK; Sen EC; Aksu AEK; Ozcan I; Altuntas Y; Gurel MS
    Sisli Etfal Hastan Tip Bul; 2022; 56(3):375-380. PubMed ID: 36304224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database.
    Reolid A; Muñoz-Aceituno E; Rodríguez-Jiménez P; González-Rojano E; Llamas-Velasco M; Fraga J; Daudén E
    Int J Dermatol; 2020 Feb; 59(2):197-206. PubMed ID: 31605541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl-peptidase IV inhibitors (DPP4i)-associated bullous pemphigoid: Estimating the clinical profile and exploring intraclass differences.
    Kridin K
    Dermatol Ther; 2020 Jul; 33(4):e13790. PubMed ID: 32506731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the Clinical Characteristics of Dipeptidyl Peptidase-4 Inhibitor-Induced Bullous Pemphigoid.
    Sun L; Wang C; Wu C; Zhou Y; Wang C
    Ann Pharmacother; 2022 Feb; 56(2):205-212. PubMed ID: 34105395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study.
    Ständer S; Schmidt E; Zillikens D; Ludwig RJ; Kridin K
    Am J Clin Dermatol; 2021 Jan; 22(1):117-127. PubMed ID: 33026629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation.
    Kridin K; Avni O; Damiani G; Tzur Bitan D; Onn E; Weinstein O; Cohen AD
    Arch Dermatol Res; 2023 Jan; 315(1):33-39. PubMed ID: 35032198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of dipeptidyl peptidase-4 inhibitor on incidence and clinical course in bullous pemphigoid patients in a tertiary medical center.
    Hsu YA; Yang TT; Huang SM; Lan CE
    Kaohsiung J Med Sci; 2023 Oct; 39(10):1038-1044. PubMed ID: 37530673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: A retrospective cohort study.
    Guo JY; Chen HH; Yang YC; Wu PY; Chang MP; Chen CC
    J Diabetes Complications; 2020 Mar; 34(3):107515. PubMed ID: 31932172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature.
    Mai Y; Nishie W; Sato K; Hotta M; Izumi K; Ito K; Hosokawa K; Shimizu H
    Front Immunol; 2018; 9():542. PubMed ID: 29706950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: A population-based cohort study.
    Wu CY; Wu CY; Li CP; Chou YJ; Lin YH; Chang YT
    Diabetes Res Clin Pract; 2021 Jan; 171():108546. PubMed ID: 33232759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid.
    Kinyó Á; Hanyecz A; Lengyel Z; Várszegi D; Oláh P; Gyömörei C; Kálmán E; Berki T; Gyulai R
    J Clin Med; 2021 Apr; 10(9):. PubMed ID: 33925042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis.
    Phan K; Charlton O; Smith SD
    Australas J Dermatol; 2020 Feb; 61(1):e15-e21. PubMed ID: 31215644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study.
    Bukvić Mokos Z; Petković M; Balić A; Marinović B
    Croat Med J; 2020 Apr; 61(2):93-99. PubMed ID: 32378375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining dipeptidyl peptidase-4 inhibitors-related bullous pemphigoid: A single-centre retrospective study.
    Nieto-Benito LM; Bergón-Sendín M; Pulido-Pérez A; Rosell-Díaz ÁM; Parra-Blanco V; Suárez-Fernández R
    Exp Dermatol; 2021 Sep; 30(9):1345-1351. PubMed ID: 34028898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Features and Outcomes of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid (DPP4i-Associated BP) in Thai Patients.
    Thewjitcharoen Y; Wanothayaroj E; Thammawiwat C; Porramatikul S; Vorayingyong C; Nakasatien S; Krittiyawong S; Chanprapaph K; Himathongkam T
    Case Rep Endocrinol; 2020; 2020():8832643. PubMed ID: 33101737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients.
    Kawaguchi Y; Shimauchi R; Nishibori N; Kawashima K; Oshitani S; Fujiya A; Shibata T; Ohashi N; Izumi K; Nishie W; Shimizu H; Arima H; Sobajima H
    J Diabetes Investig; 2019 Mar; 10(2):392-398. PubMed ID: 29920976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials.
    Silverii GA; Dicembrini I; Nreu B; Montereggi C; Mannucci E; Monami M
    Endocrine; 2020 Sep; 69(3):504-507. PubMed ID: 32236820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of IL-10 and IL-35 in dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.
    Kokubu H; Takahashi T; Kabuto M; Kouzaki H; Fujimoto N
    Exp Dermatol; 2023 Sep; 32(9):1569-1574. PubMed ID: 37424368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland.
    Benzaquen M; Borradori L; Berbis P; Cazzaniga S; Valero R; Richard MA; Feldmeyer L
    J Am Acad Dermatol; 2018 Jun; 78(6):1090-1096. PubMed ID: 29274348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
    Mai Y; Nishie W; Izumi K; Shimizu H
    Front Immunol; 2019; 10():1224. PubMed ID: 31191560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.